Biologics‐Based Therapy for the Treatment of Rheumatoid Arthritis

[1]  M. Lunt,et al.  SAT0148 Does depression affect response to anti-tumour necrosis factor-α therapy in patients with rheumatoid arthritis (RA)? Results from the british society for rheumatology biologics register (BSRBR) , 2013 .

[2]  P. Tugwell,et al.  Etanercept for the treatment of rheumatoid arthritis. , 2013, The Cochrane database of systematic reviews.

[3]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[4]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[5]  D. Solomon,et al.  Observational Studies on the Risk of Cancer Associated with TNF-Inhibitors in RA: A Review of their Methodologies and Results , 2012 .

[6]  D. Solomon,et al.  Observational Studies on the Risk of Cancer Associated with TNF-Inhibitors in RA: A Review of their Methodologies and Results , 2012 .

[7]  R. Panush.  Observational Studies on the Risk of Cancer Associated With Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Review of Their Methodologies and Results , 2012 .

[8]  D. Solomon,et al.  Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. , 2012, Arthritis and rheumatism.

[9]  K. Tyler,et al.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. , 2011, Archives of neurology.

[10]  T. Zeller,et al.  Summary of NICE guidance , 2011, Heart.

[11]  J. Doshi,et al.  Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. , 2011, Clinical therapeutics.

[12]  Tsutomu Takeuchi,et al.  Concise Report , 2005 .

[13]  Mahboob Rahman,et al.  Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years , 2011 .

[14]  R. V. van Vollenhoven,et al.  When to initiate and discontinue biologic treatments for rheumatoid arthritis? , 2011, Journal of internal medicine.

[15]  G. Wu,et al.  Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. , 2011, Clinical and experimental rheumatology.

[16]  K. Bendtzen.  Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? , 2011, Arthritis and rheumatism.

[17]  D. Symmons,et al.  Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register , 2011, Annals of the rheumatic diseases.

[18]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.

[19]  G. Guyatt,et al.  Adverse effects of biologics: a network meta-analysis and Cochrane overview. , 2011, The Cochrane database of systematic reviews.

[20]  David T Felson,et al.  UvA-DARE (Digital Academic Repository) American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials , 2011 .

[21]  C. Bombardier,et al.  Cost‐effectiveness of biologic response modifiers compared to disease‐modifying antirheumatic drugs for rheumatoid arthritis: A systematic review , 2011, Arthritis care & research.

[22]  S. Bae,et al.  The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials , 2011, Rheumatology International.

[23]  N. Bansback,et al.  Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis , 2011, Clinical Rheumatology.

[24]  G. Jürgens,et al.  Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. , 2010, Arthritis and rheumatism.

[25]  P. Geborek,et al.  Utility‐based outcomes made easy: The number needed per quality‐adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden , 2010, Arthritis care & research.

[26]  D. Felson,et al.  Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. , 2010, Rheumatology.

[27]  Alex J. Sutton,et al.  The effectiveness of anti-TNF-a therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis , 2010 .

[28]  D. Symmons.  Rheumatoid arthritis: assessing disease activity and outcome. , 2010, Clinical medicine.

[29]  R. Landewé,et al.  Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[30]  R. Landewé,et al.  Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA , 2010, Annals of the rheumatic diseases.

[31]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[32]  E. Keystone,et al.  Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission , 2010, Annals of the rheumatic diseases.

[33]  R. Maini.  Anti-TNF therapy from the bench to the clinic: a paradigm of translational research. , 2010, Clinical medicine.

[34]  F. Wolfe,et al.  The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study , 2010, Arthritis research & therapy.

[35]  B. Bresnihan,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 , 2009, Annals of the rheumatic diseases.

[36]  M. Dougados,et al.  Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial) , 2009, Annals of the rheumatic diseases.

[37]  W. Dixon,et al.  Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) , 2009, Annals of the rheumatic diseases.

[38]  E. Moilanen,et al.  Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. , 2009, Basic & clinical pharmacology & toxicology.

[39]  G. Kingsley,et al.  A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. , 2010, Rheumatology.

[40]  M. Suarez‐Almazor,et al.  Biologics for rheumatoid arthritis: an overview of Cochrane reviews , 2009, The Cochrane database of systematic reviews.

[41]  R. Straub,et al.  Perioperative management of immunosuppression in rheumatic diseases—what to do? , 2010, Rheumatology International.

[42]  Amy Ka Man Yung,et al.  ▼Tocilizumab for rheumatoid arthritis , 2009, Drug and Therapeutics Bulletin.

[43]  J. Smolen,et al.  The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. , 2009, Rheumatic diseases clinics of North America.

[44]  T. Pincus,et al.  Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. , 2009, Rheumatic diseases clinics of North America.

[45]  Jasvinder A Singh,et al.  Abatacept for rheumatoid arthritis. , 2009, The Cochrane database of systematic reviews.

[46]  G. Wells.  Patient-Driven Outcomes in Rheumatoid Arthritis , 2009, The Journal of Rheumatology.

[47]  M. Khraishi.  Comparative Overview of Safety of the Biologics in Rheumatoid Arthritis , 2009, The Journal of Rheumatology.

[48]  A. Cope,et al.  New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? , 2009, Annals of the rheumatic diseases.

[49]  A. Perdriger.  Infliximab in the treatment of rheumatoid arthritis , 2009, Biologics : targets & therapy.

[50]  N. Nishimoto,et al.  Clinical value of blocking IL-6 receptor , 2009, Current opinion in rheumatology.

[51]  X. Mariette,et al.  Abatacept therapy and safety management. , 2009, Joint, bone, spine : revue du rhumatisme.

[52]  J. Tosh,et al.  Management of rheumatoid arthritis: summary of NICE guidance , 2009, BMJ : British Medical Journal.

[53]  J. Listing,et al.  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. , 2009, JAMA.

[54]  P. Leffers,et al.  An Overview of Systematic Reviews , 2009 .

[55]  J. Listing,et al.  Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide , 2009, Annals of the rheumatic diseases.

[56]  T. Einarson,et al.  The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.

[57]  J. K. Pedersen,et al.  Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources , 2009, Rheumatology International.

[58]  D. Symmons,et al.  Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry , 2008 .

[59]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[60]  G. Kalliolias,et al.  The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis , 2008 .

[61]  K. Lohr,et al.  Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis , 2008, Annals of Internal Medicine.

[62]  V. Strand,et al.  Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results , 2007, Annals of the rheumatic diseases.

[63]  J. Leach,et al.  Guideline Development Group , 2008 .

[64]  S. Berney.  Comparison of Treatment Strategies in Early Rheumatoid Arthritis: A Randomized Trial , 2008 .

[65]  G. Kalliolias,et al.  The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. , 2008, Expert opinion on investigational drugs.

[66]  R. V. van Vollenhoven.  Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. , 2008, Rheumatology.

[67]  G. Jamtvedt,et al.  Effectiveness of Nonpharmacological and Nonsurgical Interventions for Patients With Rheumatoid Arthritis: An Overview of Systematic Reviews , 2007, Physical Therapy.

[68]  A. Cotten,et al.  Early rheumatoid arthritis: a review of MRI and sonographic findings. , 2007, AJR. American journal of roentgenology.

[69]  M. Dougados,et al.  Disease activity measures for rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.

[70]  V. Bykerk,et al.  Etanercept in the treatment of rheumatoid arthritis , 2007, Therapeutics and clinical risk management.

[71]  A. Brennan,et al.  Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. , 2007, Rheumatology.

[72]  G. Silverman.  Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. , 2006, Arthritis and rheumatism.

[73]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[74]  B. Hernández-Cruz,et al.  Adalimumab for treating rheumatoid arthritis. , 2005, The Journal of rheumatology.

[75]  F. Wolfe,et al.  The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. , 2005, Arthritis and rheumatism.

[76]  G. Kingsley,et al.  Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria. , 2005, Rheumatology.

[77]  A. Silman,et al.  The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. , 2002, Rheumatology.

[78]  E. Keystone,et al.  The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[79]  M. Feldmann,et al.  Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.

[80]  P Barton,et al.  The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. , 2002, Health technology assessment.

[81]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[82]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[83]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[84]  F. Breedveld,et al.  Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. , 1998, Arthritis and rheumatism.

[85]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.